VIR BIOTECHNOLOGY, INC. (VIR): Price and Financial Metrics


1.06 (+2.64%)

POWR Rating

Component Grades













Add VIR to Watchlist
Sign Up

Industry: Biotech


of 508

in industry


  • Growth is the dimension where VIR ranks best; there it ranks ahead of 90.32% of US stocks.
  • VIR's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • VIR's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).

VIR Stock Summary

  • VIR's went public 2.04 years ago, making it older than just 3.62% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 440.18%, Vir Biotechnology Inc's debt growth rate surpasses 97.23% of about US stocks.
  • As for revenue growth, note that VIR's revenue has grown 143.32% over the past 12 months; that beats the revenue growth of 95.18% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vir Biotechnology Inc are INO, SYRS, PTGX, NRIX, and ARCT.
  • VIR's SEC filings can be seen here. And to visit Vir Biotechnology Inc's official web site, go to

VIR Valuation Summary

  • VIR's EV/EBIT ratio is -20.4; this is 169.62% lower than that of the median Healthcare stock.
  • VIR's EV/EBIT ratio has moved down 7.7 over the prior 23 months.
  • Over the past 23 months, VIR's EV/EBIT ratio has gone down 7.7.

Below are key valuation metrics over time for VIR.

Stock Date P/S P/B P/E EV/EBIT
VIR 2021-08-31 36.8 9.1 -22.6 -20.4
VIR 2021-08-30 35.6 8.8 -21.9 -19.6
VIR 2021-08-27 35.7 8.8 -21.9 -19.7
VIR 2021-08-26 36.1 8.9 -22.2 -19.9
VIR 2021-08-25 35.3 8.7 -21.7 -19.4
VIR 2021-08-24 35.6 8.8 -21.9 -19.6

VIR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VIR has a Quality Grade of C, ranking ahead of 68.97% of graded US stocks.
  • VIR's asset turnover comes in at 0.18 -- ranking 209th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VIR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.180 0.994 -1.000
2021-03-31 0.079 1.000 -1.298
2020-12-31 0.101 1.000 -1.042
2020-09-30 0.116 1.000 -0.987
2020-06-30 0.144 1.000 -0.971
2019-12-31 0.023 1.000 -1.077

VIR Price Target

For more insight on analysts targets of VIR, see our VIR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $69.86 Average Broker Recommendation 1.69 (Moderate Buy)

VIR Stock Price Chart Interactive Chart >

Price chart for VIR

VIR Price/Volume Stats

Current price $41.27 52-week high $141.01
Prev. close $40.21 52-week low $25.31
Day low $40.36 Volume 587,500
Day high $41.40 Avg. volume 1,167,990
50-day MA $44.73 Dividend yield N/A
200-day MA $47.18 Market Cap 5.39B


Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA.

VIR Latest News Stream

Event/Time News Detail
Loading, please wait...

VIR Latest Social Stream

Loading social stream, please wait...

View Full VIR Social Stream

Latest VIR News From Around the Web

Below are the latest news stories about Vir Biotechnology Inc that investors may wish to consider to help them evaluate VIR as an investment opportunity.

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of Hold from Brokerages

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have been given an average recommendation of Hold by the eight analysts that are covering the stock, reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month []

Dakota Financial News | October 22, 2021

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021. The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology c

Yahoo | October 21, 2021

Vicki L. Sato Sells 15,174 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 15,174 shares of the firms stock in a transaction on Tuesday, October 19th. The shares were sold at an average price of $39.56, for a total value of $600,283.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the []

Transcript Daily | October 20, 2021

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place virtually from November 12-15, 2021. Among the accepted abstracts is an oral presentation of new data from a Phase 2 study ev

Yahoo | October 15, 2021

Here's Why We're Not At All Concerned With Vir Biotechnology's (NASDAQ:VIR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | October 7, 2021

Read More 'VIR' Stories Here

VIR Price Returns

1-mo -5.82%
3-mo 11.39%
6-mo -13.72%
1-year 15.38%
3-year N/A
5-year N/A
YTD 54.11%
2020 112.96%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8307 seconds.